HEME Home Transfusion Program
Recruiting
N/A
Interventional Study
Leukemia
Myeloma
Myelodysplastic Syndromes
Hematologic Malignancy
Hematologic Diseases
Lymphoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Supportive Care
- Participants needed
- 700 (estimated)
- Sponsor
- Dana-Farber Cancer Institute · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria for Patient Participants:
* Diagnosis of a relapsed/refractory hematologic malignancy
* Age ≥ 18 years
* Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment)
* Has received at least one red blood cell (RBC) or platelet transfus…
Contacts